Literature DB >> 15158520

The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals.

Gerald Reaven1.   

Abstract

The goal of this article is to differentiate the insulin resistance syndrome from the metabolic syndrome. In the case of the insulin resistance syndrome, the abnormalities and clinical syndromes that are increased in prevalence in insulin-resistant individuals have been summarized, with a brief discussion of the causal relationship between insulin resistance, compensatory hyperinsulinemia, and associated consequences. Discussion of the metabolic syndrome has focused on the five criteria chosen by the adult treatment panel III to diagnose the syndrome, evaluating them in terms of their relationship to insulin resistance and their role as cardiovascular disease risk factors.

Entities:  

Mesh:

Year:  2004        PMID: 15158520     DOI: 10.1016/j.ecl.2004.03.002

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  92 in total

Review 1.  Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Metin Basaranoglu; Serra Kayacetin; Nevin Yilmaz; Ertugrul Kayacetin; Orhan Tarcin; Abdullah Sonsuz
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Plasma adiponectin and insulin resistance in new onset hypertension.

Authors:  Teoman Dogru; Alper Sonmez; Ilker Tasci; M Ilker Yilmaz; Selim Kilic; Taner Ozgurtas; Tayfun Eyileten; M Kemal Erbil; I Hakki Kocar
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

3.  The operative risk factors in the metabolic syndrome: is it lipids and high BP or are there direct vascular effects of insulin resistance and obesity.

Authors:  Fabrice M A C Martens; Frank L J Visseren
Journal:  Curr Diab Rep       Date:  2007-02       Impact factor: 4.810

4.  Effect of Renin-Angiotensin system inhibition on cardiovascular events in older hypertensive patients with metabolic syndrome.

Authors:  Hala H Zreikat; Spencer E Harpe; Patricia W Slattum; D'arcy P Mays; Paulina A Essah; Kai I Cheang
Journal:  Metabolism       Date:  2013-11-16       Impact factor: 8.694

5.  Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate 1 and inhibit tyrosine phosphorylation.

Authors:  Nancy J Hançer; Wei Qiu; Christine Cherella; Yedan Li; Kyle D Copps; Morris F White
Journal:  J Biol Chem       Date:  2014-03-20       Impact factor: 5.157

6.  Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension.

Authors:  Egidio Imbalzano; Marco Vatrano; Sebastiano Quartuccio; Rossella Di Stefano; Caterina Oriana Aragona; Federica Mamone; Angela D'Ascola; Michele Scuruchi; Francesca Felice; Giovanni Trapani; Angela Alibrandi; Vincenzo Antonio Ciconte; Roberto Ceravolo; Antonino Saitta; Giuseppe Mandraffino
Journal:  Mol Cell Biochem       Date:  2017-02-11       Impact factor: 3.396

Review 7.  Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components.

Authors:  Girardin Jean-Louis; Ferdinand Zizi; Luther T Clark; Clinton D Brown; Samy I McFarlane
Journal:  J Clin Sleep Med       Date:  2008-06-15       Impact factor: 4.062

8.  Fructose-fed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes.

Authors:  Andrew A Bremer; Kimber L Stanhope; James L Graham; Bethany P Cummings; Wenli Wang; Benjamin R Saville; Peter J Havel
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

Review 9.  Non-alcoholic fatty liver disease and psoriasis: So far, so near.

Authors:  Giulia Ganzetti; Anna Campanati; Annamaria Offidani
Journal:  World J Hepatol       Date:  2015-03-27

10.  Plasma lipid concentrations in nondiabetic African American adults: associations with insulin resistance and the metabolic syndrome.

Authors:  Elizabeth Stein; Harvey Kushner; Samuel Gidding; Bonita Falkner
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.